TickerFacts.

Jyong Biotech Ltd. (MENS): Operating Income

Annual figures by period end, from SEC filings.

-$2.61M
Year ended 2025-12-31
2023-12-31: -$2.80M2024-12-31: -$2.06M2025-12-31: -$2.61M-$2.61M
2023-12-31 Operating Income (USD) 2025-12-31
Period endedOperating IncomeChange YoYSource filing
2025-12-31-$2.61Mn/m2026-05-15, From 2025-01-01
2024-12-31-$2.06Mn/m2026-05-15, From 2024-01-01
2023-12-31-$2.80Mn/a2026-05-15, From 2023-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating IncomeChange YoY
Jyong Biotech Ltd. (MENS)2025-12-31-$2.61Mn/m
Abvc Biopharma, Inc. (ABVC)2025-12-31-$7.15Mn/m
Annovis Bio, Inc. (ANVS)2025-12-31-$29.70Mn/m
Nexentis Technologies Inc. (NXTS)2025-12-31-$4.23Mn/m
Evofem Biosciences, Inc. (EVFM)2025-12-31$3.37Mn/m
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$231.0Kn/m
Phio Pharmaceuticals Corp. (PHIO)2025-12-31-$9.22Mn/m
BriaCell Therapeutics Corp. (BCTX)2025-07-31-$27.20Mn/m
Galectin Therapeutics Inc (GALT)2025-12-31-$20.09Mn/m

Compare MENS, ABVC, ANVS, NXTS side by side · Screen every company in Pharmaceutical Preparations ↗